T3	Treatment 0 17	Subcutaneous IL-2
T4	Effect 53 71	mortality rate <3%
T6	Route 0 12	Subcutaneous
T7	Drug 13 17	IL-2
T5	Adverse_event 46 50	with
E1	Adverse_event:T5